Demand pull is outrunning the plan for one still-small offering, and the company is visibly re-pointing itself at it
The model's full reasoning — Q2 2021 call → NOWe need to answer YES or NO based on the transcript. The question asks: does management describe ONE identifiable offering or initiative that is still a clearly smaller part of the company's overall results today, for which BOTH: (1) customer response is running ahead of what the company had prepared for (current uptake stronger/faster/broader than planned), and (2) the company is responding right now by putting more of itself behind it (concrete steps already underway to enlarge commitment). We need to find such an offering in the transcript. The transcript mentions several: Tenable.ep, Tenable.ot, Tenable.ad, cloud offerings (Tenable.io), etc. We need to see if any of these have both conditions. Let's scan the transcript for mentions of specific offerings and any statements about demand exceeding preparation and current response. - Tenable.ep: Amit says "our newly launched Tenable.ep, which brings together vulnerability management, web application security, container security and lumen into a single offering, has been a catalyst of growth here and for larger deals, and validates our holistic approach to assessing risk." Steve says "EP is driving higher deal sizes... average deal size is about 55% to 60% higher than if we would sell core VM on a standalone basis." But is there any statement that customer response is running ahead of what the company had prepared for? Not explicitly. They say it's a catalyst, but no mention of demand exceeding preparation. Also, is the company responding by putting more behind it? They mention investments in sales and marketing, but not specifically for EP. They say "we're also seeing higher attach rates" but no explicit "we are scaling up capacity for EP because demand is ahead." So likely not. - Tenable.ot: Amit says "OT continues to see strong traction... early deployments have been successful and we see expanded business opportunities... In the quarter, we had a great six figure cross-sell win with a large public utility provider." Steve says "we're absolutely focused on investing more in OT. Penetration is still relatively modest and market opportunity is large.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| HCKT | The Hackett Group, Inc. | Q1 2024 | 2024-05-08 | C |
| ROCK | Gibraltar Industries, Inc. | Q1 2024 | 2024-05-01 | B+ |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| ESRT | Empire State Realty Trust, Inc. | Q2 2021 | 2021-07-29 | C+ |
HCKT · Q1 2024 → YESThe question is about whether management describes one identifiable offering that's still small, where customer response is ahead of what they prepared for, AND they're responding now by putting more ...YES The transcript describes AI Explorer (the GenAI assessment platform) as a small, early-stage offering (nominal Q1 revenue impact, part of broader GenAI pivot). Management states customer response is exceeding preparation: "over 175 demo meetings with many more scheduled... resulted in a number of new enterprise...
SYY · Q1 2023 → YESThe question is about whether management describes one identifiable offering or initiative that's still a smaller part of the business, where customer response is running ahead of what they prepared f...YES The transcript shows that Sysco Your Way is presented as a smaller, still-developing offering (described as part of the Recipe For Growth pillars, with its scale expected to grow each quarter and currently limited to specific neighborhoods and recent international rollouts like Toronto and Dublin).
PRPH · Q1 2023 → YESThe question asks if management describes one identifiable offering that's still a smaller part of the business, where customer response is running ahead of what they prepared for, AND they're respond...YES The lozenge manufacturing facility is the clearest match. It is explicitly described as “the least interesting business we’re developing” and still a smaller slice of overall results (COVID testing was the dominant revenue driver for the prior two years).